CD22-directed Antibody Interactions [MoA] class drugs

1 result

  • besponsa - inotuzumab ozogamicin injection, powder, lyophilized, for solution

    (Inotuzumab Ozogamicin)
    Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.
    Besponsa treats relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adults and pediatric patients aged 1 year and older.
    Medication Details
    Savings Programs
    1
    Drug Interactions